Jeena Sikho Lifecare Ltd

- Manish Grover mentioned a budget of around INR 7.75 crores for adding a 300-bed hospital in Meerut, Chandigarh, Rajpura. - For adding 500 beds over the next 2-3 years, total capex is estimated between INR 15 to 20 crores. - The company primarily takes hospitals on rent and only invests in interiors, reducing upfront capex burden. - There is no explicit mention of new fundraising through debt or equity in the discussed transcript. - The expansion and capex appear to be managed through operational cash flows or owner contributions rather than new fundraising. - The company plans to increase bed capacity by 500-600 beds every year over the next 5 years, indicating ongoing capital requirements, but no direct fundraising announcements.

- Planned addition of 500 new beds by FY2025, with capex of approximately INR3 lakh per bed (INR15 crores to INR20 crores for 500 beds). - Specific hospital investments include 300 beds in Meerut, Chandigarh, Rajpura with a budget of around INR7.75 to 9 crores. - Continued focus on adding 500-600 beds every year for the next 3-5 years, aiming to reach 3,000 beds in 3 years and above 4,000 beds in 5 years. - New hospitals planned in Uttar Pradesh (Meerut - 350 beds, Lucknow - 100 beds, plus Kanpur, Agra, Banaras, Saharanpur, and potential hospital in Noida). - Capex spent in FY24 was INR80 crores. - No direct ownership of hospitals; properties are taken on rent with capex focused primarily on interiors. - Strategic emphasis on NABH accreditation and cashless treatment integration in Ayurveda. - Expansion plans include entering international markets like Mauritius, Dubai, and Canada with clinics/hospitals.

- Targeting 55% occupancy in FY '25, leading to revenue of around INR 450 crores. - Planning to add 500 new hospital beds by March 2025, with incremental revenue expected from these additions. - Revenue expected to reach INR 600-650 crores by FY '26 with 85% occupancy on older beds and 35% on 500 new beds. - PAT margin projected to exceed 25% due to controlled expenses despite expansion. - Medicine vertical grew by 32% YoY, with plans to launch 10 OTC patented formulas priced between INR 150-600. - Focus on increasing patient awareness about cashless health insurance since April 2024, aiding revenue growth. - Long-term plan to have 3,000 beds in 3 years and over 4,000 beds in 5 years, aiming to become India’s number one Ayurvedic healthcare company. - Expanding in new segments such as infertility, heart, and liver diseases. - International expansion underway with plans for centers in Mauritius and approvals in 112 countries.

- Target revenue for FY25 is around INR 450 crores with a PAT margin of approximately 25%. - Occupancy increase from current 37% to 55% expected to drive 50% growth in profit; potential to triple profit if occupancy reaches 80%. - Plans to add 500 new beds by March 2025, with some beds operational mid-year, enhancing revenue and profit. - Long-term target to scale to 3,000 beds in 3 years and over 4,000 beds in 5 years, supporting sustained growth. - EBITDA and profit margins are improving, with FY24 showing 29% EBITDA margin and 21% PAT margin. - Profit has grown faster than revenue, e.g., profit grew 3.75 times from 2022 to 2023 while revenue doubled. - Expansion facilitated by government backing, increased insurance cashless benefits, and strong product portfolio growth.

- The transcript does not explicitly mention current or expected order book or pending orders in numeric terms. - However, Manish Grover discussed a robust expansion plan including adding 500 new beds by March 2025, increasing total beds from around 1,300 to 1,800. - He also mentioned plans to open 15 new hospitals within the year, focusing on areas with higher patient inquiries and government healthcare plans. - OTC medicine launches are planned within 3 to 6 months after market surveys, targeting chronic diseases with potentially large patient bases. - The company is aiming to increase hospital occupancy from 37% to 55% in FY25, which would significantly boost revenues. - Government support includes cashless health insurance starting April 2024, expected to improve patient inflow and order flow. - Overall, the business pipeline looks strong with ongoing capacity additions and product launches, implying a growing order inflow though exact order book numbers are not disclosed.